Shares Sink 38% After-Hours as Candel Updates Application Timing
CADL sits 17% above its 52-week low of $4.35.
Summary
Candel fell 38% in after-hours trading Thursday after an update on application timing, with shares closing the regular session at $8.39, down 9%. The company also started the first site in its Phase 3 AURORA trial, testing aglatimagene plus valacyclovir and pembrolizumab against docetaxel in metastatic non-squamous lung cancer. On Nov. 12, 2026, Candel amended its sale agreement with Jefferies, allowing it to offer up to $50 million in common stock. The timing update is the driver here: it lands the day after the Q3 8-K disclosed a widened $21.9 million net loss and a mid-2027 BLA submission target, so any perceived slippage in that timeline hits a stock already digesting higher R&D spend. The fresh $50 million ATM adds dilution overhang on top of the selloff.
At the time of this announcement, CADL was trading at $5.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642M. The 52-week trading range was $4.35 to $14.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.